Pharmacokinetic comparison of subcutaneously administered CT ‐ P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants
Clinical and Translational Science · 2024
DOI: 10.1111/cts.70037 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Ye Chan Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Center, Chungnam National University Hospital, Daejeon, Korea. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Syringes, Infliximab, Healthy Volunteers. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
CT‐P13, a biosimilar of infliximab, is used to treat inflammatory diseases that arise from immune system complications, resulting in excessive and persistent inflammation. The subcutaneous (SC) formulation of CT‐P13 overcomes the drawback of prolonged administration associated with the intravenous (IV) infliximab biosimilar, necessitating autoinjector (AI) administration. This randomized, open‐label, two‐arm, parallel‐group, single‐dose clinical pharmacology study aimed to evaluate the pharmacokinetics (PK) and safety of CT‐P13 SC administration via AI compared with the existing pre‐filled syringe (PFS) method. A total of 147 healthy participants were randomized into two groups, of which 139 completed the study. Blood samples were collected from before CT‐P13 SC administration to 2016 h after the start of the administration. Serum concentrations were analyzed using the Meso Scale Discovery electrochemiluminescence method. Geometric mean ratios (90% confidence interval) of the AUC inf (areas under the concentration–time curve from zero to infinity) and C max (The maximum serum concentration) for CT‐P13 SC AI versus CT‐P13 SC PFS groups, were 94.15% (85.02%–104.26%), 92.48% (84.66%–101.01%), respectively. CT‐P13 SC AI and CT‐P13 SC PFS achieved comparable PK because the 90% CI was within the predefined equivalence margin. At the end of the study, immunogenicity results revealed that 70 (97.22%) and 73 (98.65%) participants tested positive for anti‐drug antibody (ADA) in the CT‐P13 SC AI and CT‐P13 SC PFS groups, respectively. They were tested positive for neutralizing antibodies. No other significant safety differences were observed between the treatment groups. In conclusion, both administrations demonstrated PK equivalence and were both safe and well‐tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Trials Center, Chungnam National University Hospital, Daejeon, Korea.
- Department of Medical Science, Chungnam National University College of Medicine, Daejeon, Korea.
- Medical Science Division, Celltrion, Inc., Incheon, Korea.
- Department of Pharmacology, Chungnam National University College of Medicine, Daejeon, Korea.
- Department of Family Medicine, Chungnam National University Hospital, Daejeon, Korea.
ORCID-Profile: Ye Chan Park, Jae Hoon Kim, Ju Hyun Lee, Jang Hee Hong, Jin-Gyu Jung, Jung Sunwoo
Zitieren
APA
Park, Y. C., Kim, J. H., Kim, S. H., Lee, J. H., Hong, J. H., Jung, J. G., & Sunwoo, J. (2024). Pharmacokinetic comparison of subcutaneously administered CT ‐ P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants. Clinical and Translational Science. https://doi.org/10.1111/cts.70037
Vancouver
Park YC, Kim JH, Kim SH, Lee JH, Hong JH, Jung JG, et al. Pharmacokinetic comparison of subcutaneously administered CT ‐ P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants. Clinical and Translational Science. 2024. doi:10.1111/cts.70037
BibTeX
@article{Park2024,
author = {Park, Ye Chan and Kim, Jae Hoon and Kim, Sung Hyun and Lee, Ju Hyun and Hong, Jang Hee and Jung, Jin-Gyu and Sunwoo, Jung},
title = {Pharmacokinetic comparison of subcutaneously administered CT ‐ P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.70037}
}
EUVIMED